Merck says will not seek approval of cholesterol treatment

(Reuters) – Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.

Powered by WPeMatico

Leave a Reply

Your email address will not be published. Required fields are marked *